GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Capex-to-Operating-Cash-Flow

Conduit Pharmaceuticals (FRA:ZK7) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Conduit Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2025 was €-0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was €-4.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Conduit Pharmaceuticals Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Capex-to-Operating-Cash-Flow Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
- - - -

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.


;
;

Conduit Pharmaceuticals Capex-to-Operating-Cash-Flow Calculation

Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.049) / -9.246
=N/A

Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.004) / -4.004
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conduit Pharmaceuticals  (FRA:ZK7) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Conduit Pharmaceuticals Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines